Autonomic Phenotype Before and After Akt Inhibition

Vanderbilt University

Status: Withdrawn

Conditions: Diagnosis of Melanoma

Treatments: Behavioral: Autonomic Function Tests; Other: supine and standing catecholamines

Study type: Observational

Funder types: Other

Identifiers

NCT01593579

VR3689 (Other Identifier)

120390

Details and patient eligibility

About

Some Akt inhibitors have produced functional cardiovascular effects such as marked hypotension that may limit their clinical benefit. There are no current data on whether this autonomic failure presents in humans at clinically used doses. We will test the hypothesis that Akt inhibition causes an acute decrease in sympathetic tone and lowers blood pressure.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with melanoma with a BRAF mutation and relapse following therapy with a BRAF inhibitor
• Enrolled in a clinical trial through the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
• Able and willing to provide informed consent

Exclusion criteria

• Factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
• Unable to give informed consent

Trial design

0 participants in 1 patient group

Patients with Melanoma

Description:

Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor

Treatment:

Other: supine and standing catecholamines

Behavioral: Autonomic Function Tests